It is known that >70% of the genes involved in pathogenic hearing loss are involved in autosomal recessive nonsyndromic hearing loss (ARNSHL), which accounts for 1 case for every 166 individuals in Iran due to the high rate of consanguineous marriage in the country.
Bright Peak Therapeutics Inc. has raised $90 million in a series C financing. Proceeds will be used to accelerate a pipeline of next-generation immunotherapies and advance BPT-567 into a phase I/IIa trial.
Researchers from Alteogen Inc. and affiliated organizations presented preclinical characterization of a novel long-acting growth hormone receptor (GHR) antagonist, ALT-B5.
Scientists from the Karolinska Institute have found two different types of cells that give rise to the fibroblasts that form fibrotic scars after spinal cord injury (SCI) depending on their location. In a study in mice, the researchers observed that pericytes acted in lesions that affect the gray matter and perivascular fibroblasts acted in the white matter.
Work at Open Source Therapeutics has led to the preparation of pyridone compounds acting as phosphodiesterase PDE3A/SLFN12 interaction inducers reported to be useful for the treatment of cancer.
Incyte Corp. has patented heteroaryl fluoroalkenes acting as diacylglycerol kinase α (DGK-α) and/or diacylglycerol kinase ζ (DGK-ζ) inhibitors and thus reported to be useful for the treatment of cancer.
Rome Therapeutics Inc. has synthesized cyclopentene-oxymethylene phosphonamidate compounds acting as LINE-1 retrotransposable element ORF1 protein (L1RE1) and/or HERV-K reverse transcriptase inhibitors.
An Eli Lilly & Co. patent describes new glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes type 2, hyperglycemia and obesity.
Genetic variants in core-spliceosome components are tied to a variety of aberrant splicing-driven inherited disorders. CWF19-like protein 2 (CWF19L2) is such a key component located in the spliceosome complex in charge of maturing pre-RNA. No disease-phenotype has been established for CWF19L2.
RSS
